NUR 635 Topic 3 (2026) – 200+ Questions on Epilepsy, RA, Parkinson’s, Osteoporosis, Gout & Dementia

This NUR 635 Topic 3 (2026) exam guide contains over 200 structured and verified questions covering epilepsy management, antiepileptic drugs (AEDs), rheumatoid arthritis pharmacotherapy, Parkinson’s disease treatment, osteoporosis therapies, gout management, and dementia medications. The material begins with seizure classification (focal, generalized, unknown onset), first-line benzodiazepine use in acute seizures, broad vs narrow spectrum AEDs, serious dermatologic reactions (SJS/TEN), drug–drug interactions (e.g., valproic acid with lamotrigine), and monitoring parameters such as CBC, LFTs, ECG, and electrolyte surveillance, as outlined on pages 1–6. The guide also provides in-depth coverage of rheumatoid arthritis treatment algorithms, including methotrexate initiation within 3 months of diagnosis, folic acid supplementation, hydroxychloroquine retinopathy risk, sulfasalazine monitoring, glucocorticoid adverse effects, TNF inhibitor boxed warnings (TB reactivation), and biologic DMARD precautions. Neurologic pharmacology sections review Parkinson’s disease pathophysiology (dopamine deficiency), carbidopa/levodopa mechanisms, COMT and MAO-B inhibitors, dopamine agonists, dyskinesia management, and Beers Criteria considerations in elderly patients. Musculoskeletal content includes osteoporosis screening (BMD, T-score ≤ -2.5), FRAX scoring, bisphosphonate administration rules, raloxifene DVT risk, teriparatide osteosarcoma warning, denosumab mechanism (RANKL inhibition), glucocorticoid-induced osteoporosis management, and vitamin D toxicity symptoms. Gout management is thoroughly reviewed, including acute therapy (NSAIDs, colchicine, steroids), urate-lowering therapy targets (6 mg/dL), HLA-B*5801 screening before allopurinol in high-risk populations, xanthine oxidase inhibitors, probenecid mechanism, pegloticase indications, and monitoring labs. The final section addresses dementia types, acetylcholinesterase inhibitors, memantine (NMDA antagonist), dosing considerations, and risks of antipsychotics in elderly patients with dementia. This document may concern: – Graduate nursing students enrolled in NUR 635 – Family Nurse Practitioner (FNP) students – Adult-Gerontology NP students – Advanced pharmacology students – APRN board preparation candidates – MSN and DNP students reviewing multisystem pharmacotherapy Keywords: NUR 635 topic 3 exam 2026, epilepsy seizure classification, antiepileptic drugs AEDs, SJS TEN lamotrigine carbamazepine, valproic acid monitoring CBC LFT, rheumatoid arthritis methotrexate first line, TNF inhibitor boxed warning TB, Parkinson disease carbidopa levodopa, COMT inhibitor entacapone, MAO B inhibitor selegiline rasagiline, Beers Criteria elderly medications, osteoporosis T score minus 2.5, bisphosphonate administration upright 30 minutes, teriparatide osteosarcoma warning, denosumab RANKL inhibitor, acute gout NSAID colchicine steroid, allopurinol HLA B 5801 screening, uric acid target 6 mg dL, acetylcholinesterase inhibitors donepezil, memantine NMDA receptor antagonist, antipsychotics dementia mortality risk